mergers & acquisitions

Enliven Therapeutics, Imara Merge to Advance Precision Oncology Pipeline

Roche to Acquire Good Therapeutics for $250M

MDxHealth Acquires Prostate Cancer Testing Business From Exact Sciences for up to $100M

Ipsen Acquires Epizyme, Garners Tazverik, Other Oncology Assets

BMS to Acquire Turning Point Therapeutics in Deal Valued at $4.1B

Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor

Tempus Acquires Highline Sciences

Calibre Scientific Acquires Sequencing Sample Prep Reagent Firm BrightBox Quantitation

Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal

Predictive Oncology Acquires 3D Tumor Model Developer ZPredicta

Blueprint Medicines Acquires Lengo Therapeutics in $465M Deal

Cancer Dx Firms ACT Genomics, Sanomics Merge

ConcertAI, TeraRecon Merge to Bolster Real-World Data Analytics for Precision Oncology Research

Illumina Acquires Grail Despite Ongoing Regulatory Scrutiny

EQRx to go Public on Nasdaq Through $1.8B SPAC Deal With CM Life Sciences III

Bayer Acquires Vividion Therapeutics for up to $2B

Kiromic BioPharma Acquires InSilico Solutions

Dante Labs Acquires Cambridge Cancer Genomics

Veracyte to Acquire HalioDx for €260M

Aerpio Pharmaceuticals, Aadi Bioscience to Merge; Aim to Raise $155 in PIPE Financing